22 completed, 9 active not recruiting, 9 recruiting, 5 terminated. 17 Phase 3, 13 Phase 2, 10 Phase 1, 4 Not applicable, 2 Phase 4.
Follow Dravet Syndrome: new trials by email Literature Review of Dravet Syndrome trials Research Report on Dravet Syndrome
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| ASCEND: Safety and Tolerability of ION337 for the Treatment of Dravet Syndrome ION337 - Dravet Syndrome | Phase 1 / Phase 2 | Recruiting | Ionis Pharmaceuticals, Inc. | 32 | 2026-05-21 | 2026-09-03 |
| A PET-MRI Study of Serotoninergic Brainstem Pathway in Patients With Dravet Syndrome [18F]MPPF PET-MRI - Epilepsy, Dravet Syndrome | Not applicable | Recruiting | Hospices Civils de Lyon | 30 | 2026-05-04 | 2026-05-08 |
| The FINTEPLA as an Anti-SUDEP Therapy in Dravet Syndrome Project Fenfluramine treatment (Fintepla), Hypercapnia Challenge using the device (RespirAct) - Dravet Syndrome | Phase 4 | Recruiting | The University of Texas Health Science Center, Houston | 25 | 2026-04-27 | 2026-07-15 |
| Multicentre Real-life Follow-up Study of Rare Epileptic Syndromes in Children and Adolescents Epilepsy, West Syndrome | Recruiting | Assistance Publique - Hôpitaux de Paris | 1000 | 2025-12-11 | 2026-02-24 | |
| Longitudinal Study of Phenotypic and Developmental Severity in Patients With Dravet Syndrome With SCN1A Gene Mutation Dravet Syndrome | Recruiting | Assistance Publique - Hôpitaux de Paris | 50 | 2025-09-15 | 2026-02-03 | |
| A Double-blind Study Evaluating the Efficacy, Safety, and Tolerability of Zorevunersen in Patients With Dravet Syndrome zorevunersen, Sham Comparator - Dravet Syndrome | Phase 3 | Active not recruiting | Stoke Therapeutics, Inc | 170 | 2025-06-04 | 2026-10-20 |
| Bioavailability of Stiripentol After Single Oral Dose of Capsule vs Suspension in Healthy Subjects (STILIQ) Stiripentol capsule (Diacomit®), Stiripentol oral suspension (Diacomit®) - Dravet Syndrome, Epilepsy | Phase 1 | Completed | Biocodex | 24 | 2025-06-01 | 2025-09-16 |
| Epidyolex® in Lennox Gastaut, Dravet Syndrome and Tuberous Sclerosis Complex: an Observational Study in ITALY Epidiolex 100 mg/mL Oral Solution - Lennox Gastaut Syndrome, Dravet Syndrome | Active not recruiting | Jazz Pharmaceuticals | 111 | 2025-02-24 | 2026-06-03 | |
| BMB-101 in Absence Epilepsy and DEE BMB-101 - Absence Epilepsy, Jeavons Syndrome | Phase 2 | Recruiting | Bright Minds Biosciences Pty Ltd | 20 | 2024-12-05 | 2025-08-12 |
| A Phase 3, Placebo-Controlled Study to Investigate LP352 in Children and Adults With Dravet Syndrome (DS) LP352, Placebo - Dravet Syndrome | Phase 3 | Active not recruiting | Longboard Pharmaceuticals | 96 | 2024-09-25 | 2026-09-17 |
| A Study to Evaluate Safety, Tolerability, and Pharmacokinetics of Fenfluramine (Hydrochloride) in Infants 1 Year to Less Than 2 Years of Age With Dravet Syndrome fenfluramine - Dravet Syndrome | Phase 3 | Completed | UCB BIOSCIENCES, Inc. | 25 | 2024-05-21 | 2026-09-17 |
| A Clinical Study to Evaluate the Safety and Efficacy of ETX101 in Infants and Children With SCN1A-Positive Dravet Syndrome ETX101 - Dravet Syndrome | Phase 1 / Phase 2 | Recruiting | Encoded Therapeutics | 113 | 2024-05-14 | 2026-10-23 |
| A Clinical Study to Evaluate the Safety and Efficacy of ETX101, an AAV9-Delivered Gene Therapy in Children With SCN1A-positive Dravet Syndrome ETX101 - Dravet Syndrome | Phase 1 / Phase 2 | Active not recruiting | Encoded Therapeutics | 5 | 2024-05-09 | 2026-06-08 |
| A Clinical Study to Evaluate the Safety and Efficacy of ETX101, an AAV9-Delivered Gene Therapy in Children With SCN1A-positive Dravet Syndrome (Australia Only) ETX101 - Dravet Syndrome | Phase 1 / Phase 2 | Active not recruiting | Encoded Therapeutics | 4 | 2024-02-28 | 2025-11-14 |
| SCN1A Horizons A Natural History Study of SCN1A-related Epilepsies in the United Kingdom SCN1A, Dravet Syndrome | Unknown | NHS Greater Glasgow and Clyde | 400 | 2023-11-20 | 2024-07-16 | |
| LEONIDaS Caregivers Study Multiple - Dravet Syndrome, Depression | Withdrawn | University of Oxford | 2023-10-26 | 2023-12-14 | ||
| EXploring novEl Molecular Determinants of DRAvet Syndrome Phenotype Heterogeneity skin punch biopsy - Dravet Syndrome | Not applicable | Unknown | Fondazione Policlinico Universitario Agostino Gemelli IRCCS | 16 | 2023-07-06 | 2024-04-17 |
| Fenfluramine for Adult Dravet Patients Fenfluramine - Dravet Syndrome, Dravet Syndrome, Intractable | Phase 3 | Terminated | University Health Network, Toronto | 7 | 2023-01-11 | 2026-05-05 |
| Open-label, Long-term Safety Study of LP352 in Subjects With Developmental and Epileptic Encephalopathy LP352, bexicaserin - Developmental and Epileptic Encephalopathy, Dravet Syndrome | Phase 2 | Completed | Longboard Pharmaceuticals | 41 | 2022-11-08 | 2025-12-03 |
| Neurodevelopmental Impact of Epilepsy on Autonomic Function in Dravet Syndrome Video-electroencephalography, Blood Samples - Dravet Syndrome, Epilepsy | Not applicable | Active not recruiting | Hospices Civils de Lyon | 92 | 2022-10-14 | 2026-01-14 |
Showing 20 of 62. Sign in to see all of them.
Epilepsies, Myoclonic (62) · Epilepsy (24) · Lennox Gastaut Syndrome (14) · Seizures (10) · Tuberous Sclerosis (7) · Brain Diseases (5) · CDKL5 deficiency disorder (4) · Anemia, Sickle Cell (2) · Cystic Fibrosis (2) · Diabetes Mellitus (2) · Generalized Epilepsy With Febrile Seizures Plus, Type 2 (2) · Spasms, Infantile (2) · Sudden Unexpected Death in Epilepsy (2) · beta-Thalassemia (2) · 3-Hydroxy-3-Methylglutaryl-CoA Lyase Deficiency (1)
Epilepsy, Generalized (62) · Epileptic Syndromes (62) · Central Nervous System Diseases (61) · Nervous System Diseases (61) · Brain Diseases (57) · Epilepsy (38) · Congenital, Hereditary, and Neonatal Diseases and Abnormalities (16) · Genetic Diseases, Inborn (16) · Pathological Conditions, Signs and Symptoms (16) · Neurologic Manifestations (12) · Signs and Symptoms (11) · Neurodegenerative Diseases (9) · Congenital Abnormalities (8) · Heredodegenerative Disorders, Nervous System (8) · Neoplasms (8)
Cannabidiol (10) · Fenfluramine (10) · stiripentol (5) · Clobazam (2) · Blood Specimen Collection (1) · Curcumin (1) · Electroencephalography (1) · Retrospective Studies (1) · Solutions (1) · Suspensions (1) · Transcranial Magnetic Stimulation (1) · Verapamil (1)
Jazz Pharmaceuticals (5) · Zogenix International Limited, Inc., a subsidiary of Zogenix, Inc. (5) · Encoded Therapeutics (4) · Longboard Pharmaceuticals (4) · Gillette Children's Specialty Healthcare (3) · Stoke Therapeutics, Inc (3) · Assistance Publique - Hôpitaux de Paris (2) · Biocodex (2) · Cook Children's Health Care System (2) · Epygenix (2) · Fondazione Policlinico Universitario Agostino Gemelli IRCCS (2) · H. Lundbeck A/S (2) · Hospices Civils de Lyon (2) · University of Colorado, Denver (2) · Zogenix, Inc. (2)
United States (41) · United Kingdom (14) · Australia (13) · France (13) · Spain (10) · Canada (9) · Italy (9) · Germany (8) · Belgium (7) · Poland (5) · Denmark (4) · Japan (4) · Mexico (4) · Netherlands (4) · China (3)
Salvador Rico, M.D., Ph.D (3) · Ann Dandurand, MD (2) · Beverly S Wical, MD (2) · Dennis J Dlugos, MD (2) · Alexander Rotenberg, MD, PhD (1) · Amit Ray, MD (1) · Andreas Brunklaus, MD PhD (1) · Ann Hallemans, PhD (1) · Catherine Harmer, PhD (1) · Christos Papadelis, PhD (1) · Curt Scharfe, MD, PhD (1) · Domenica Immacolata Battaglia (1)
PMID 34768178, PMID 33540241, PMID 34265088, PMID 41780062, PMID 28538134, PMID 29768152, PMID 30644536, PMID 30940509, PMID 31315600, PMID 31582194, PMID 31790543, PMID 31862249, PMID 32119035, PMID 33230827, PMID 33445140, PMID 33445141, PMID 34287833, PMID 34406656, PMID 34666230, PMID 34676542, PMID 35142618, PMID 35841234, PMID 37543865, PMID 40072476
2014 (4), 2016 (1), 2018 (1), 2019 (1)